MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Protara Therapeutics Revenue 2011-2026 | TARA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Protara Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 2.95 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.95 M | 2.95 M | 2.95 M |
Quarterly Revenue Protara Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.95 M | 2.95 M | 2.95 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Xeris Pharmaceuticals
XERS
|
292 M | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
110 M | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
16.1 M | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
GT Biopharma
GTBP
|
27 K | $ 0.47 | -2.41 % | $ 892 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
156 M | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Agios Pharmaceuticals
AGIO
|
54 M | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
517 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
372 M | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
21 M | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Entera Bio Ltd.
ENTX
|
365 K | $ 1.38 | -0.72 % | $ 63.3 M | Israel |
 |
Altimmune
ALT
|
20 K | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
Teligent, Inc.
TLGT
|
45.3 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
8.51 M | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Viela Bio, Inc.
VIE
|
11.7 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
214 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
16.6 B | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
509 M | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
141 K | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.67 | -1.38 % | $ 2.61 B | USA |